6-Nitro-3-oxo-3,4-dihydropyrazine-2-carboxamide
CAS: 259793-97-0
Ref. 3D-JKA79397
| 1g | To inquire | ||
| 5g | To inquire | ||
| 10g | To inquire | ||
| 250mg | To inquire | ||
| 500mg | To inquire |
Product Information
Ravidasvir is a drug molecule that has been licensed for use in humans and is currently under development by Gilead Sciences. The drug has been shown to be effective against HIV-1, as well as hepatitis C virus (HCV). It is being tested as a possible treatment for chronic hepatitis B virus infection. Ravidasvir is a small molecule inhibitor of the viral protease enzyme, which prevents the release of new viruses from infected cells. Clinical trials have shown that ravidasvir can reduce both the amount of virus in patients' blood and the amount of virus in their semen. Covid-19, a drug containing ravidasvir, was approved by the FDA on December 18th, 2018. Gilead Sciences has filed patent applications for ravidasvir in more than 100 countries around the world.
Chemical properties
Technical inquiry about: 3D-JKA79397 6-Nitro-3-oxo-3,4-dihydropyrazine-2-carboxamide
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
